Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
3.040
-0.170 (-5.30%)
At close: Oct 16, 2026, 4:00 PM EDT
3.020
-0.020 (-0.66%)
After-hours: Oct 16, 2026, 7:30 PM EDT
Company Description
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States.
It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
The company was founded in 2018 and is based in Cerritos, California.
Liminatus Pharma, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Chris Kim |
Contact Details
Address: 12611 Hiddencreek Way, Unit C Cerritos, California 90703 United States | |
| Phone | 213 273 5453 |
| Website | liminatuspharma.com |
Stock Details
| Ticker Symbol | LIMN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001971387 |
| CUSIP Number | 53271X207 |
| ISIN Number | US53271X2071 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chris Kim J.D., L.L.M. | Chief Executive Officer, Chairman and President |
| Scott Dam | Chief Financial Officer |
| Dr. Beom Kyu Choi | Chief Technology Officer and Member of Scientific Advisory Board |
| Dr. Byong Chul Yoo Ph.D. | Chief Science Officer and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 29, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 4, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 24, 2026 | 8-K | Current Report |
| Jul 22, 2026 | SCHEDULE 13G | Filing |
| Jul 14, 2026 | SCHEDULE 13D/A | Filing |
| Jul 13, 2026 | DEF 14A | Other definitive proxy statements |
| Jul 6, 2026 | SCHEDULE 13G/A | Filing |